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ABSTRACT
Multipotent mesenchymal stromal cells (MSCs), often labeled mesenchymal stem cells, contribute to tissue re-
generation in injured bone and cartilage, as well as in the infarcted heart, brain, and kidney.We hypothesize that
MSCs might also contribute to pancreas and kidney regeneration in diabetic individuals. Therefore, in strepto-
zotocin (STZ)-induced type 1 diabetes C57BL/6 mice, we tested whether a single intravenous dose of MSCs led
to recovery of pancreatic and renal function and structure. When hyperglycemia, glycosuria, massive beta-pan-
creatic islets destruction, and mild albuminuria were evident (but still without renal histopathologic changes),
mice were randomly separated in 2 groups: 1 received 0.5 106MSCs that have been ex vivo expanded (and char-
acterized according to their mesenchymal differentiation potential), and the other group received the vehicle.
Within a week, only MSC-treated diabetic mice exhibited significant reduction in their blood glucose levels,
reaching nearly euglycemic values a month later. Reversion of hyperglycemia and glycosuria remained for 2
months at least. An increase in morphologically normal beta-pancreatic islets was observed only inMSC-treated
diabeticmice. Furthermore, in those animals albuminuria was reduced and glomeruli were histologically normal.
On the other side, untreated diabetic mice presented glomerular hyalinosis and mesangial expansion. Thus,
MSC administration resulted in beta-pancreatic islets regeneration and prevented renal damage in diabetic an-
imals. Our preclinical results suggest bone marrow-derived MSC transplantation as a cell therapy strategy to
treat type 1 diabetes and prevent diabetic nephropathy, its main complication.
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The predominant cause of type 1 diabetes is an
autoimmune-mediated destruction of the beta-pan-
creatic cells, and its main complication is diabetic
nephropathy. Limited supply of allogeneic beta-pan-
creatic islets and kidneys, together with complica-
tions arising from continued immune suppression,
urge the development of diabetes curative therapy
based on insulin-producing and renal cell regenera-
tion, without the requirement of patient condition-
ing. Recently, bone marrow-derived cell (BMC)
transplantation has been suggested to contribute tothe recovery of endocrine function of the pancreas in
diabetic animal models [1,2], as well as in humans [3].
However, other reports do not support such findings
[4,5]. This discrepancy may be because of the diabetes
etiology and/or stage, via BMC administration and
technical differences in the handling of donor BMCs
between different publications. In the latter case, qual-
itative and quantitative differences in the subpopula-
tions present in the infused BMCs might explain why
in some cases BMC transplantation correct hypergly-
cemia, whereas in others no evidence was found to
support this fact.631
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often labeled mesenchymal stem cells, are defined as
undifferentiated, self-renewable cells present in bone
marrow and in mesenchymal tissues [6]. These cells
do not exhibit hemopoietic markers, but express
CD73, CD90, CD105, and alpha smooth muscle actin
[7,8]. Either in vitro or in vivo, MSCs can differentiate
into adipocytes, osteoblasts, chondrocytes, tenocytes,
myocytes, hemopoietic supporting stromal cells [6-9],
and also into nonmesodermal cells from vascular,
brain, lung, kidney, and skin tissues [10-14]. In addi-
tion, MSCs have been reported as hypoimmunogenic
cells, appearing to be a perfect tool for transplantation
without recipient conditioning [15], either to induce
tissue regeneration [16,17] or to manage exacerbated
immune response [18]. Thus, bone marrow-derived
MSCs have been used successfully in cell therapy pro-
tocols to treat patients with osteogenesis imperfecta
[19], idiopathic aplastic anemia [20], myocardial in-
farction [21], and graft-versus-host disease (GVHD)
[18]. In vitro, MSCs may originate insulin-producing
cells [22-24]. Together, in vivo they differentiate into
renal cells [25,26] and may reconstitute necrotic seg-
ments of damaged kidneys [27,28]. Furthermore, on
an incomplete model for streptozotocin (STZ)-in-
duced type 2 diabetes in immunodeficient NOD/
SCID mice, an intracardiac infusion of a very high
number of MSCs (250 106/kg body weight) results
in their lodging in the pancreas and kidney, preventing
further damage [29]. Both in vitro and in vivo, MSCs
behave as immunomodulatory cells that may control
inflammatory processes, thus preventing cell destruc-
tion by the immune system [30].
Based on the above facts, we propose the hypothesis
that systemically administered bone marrow-derived
MSCsmight contribute to the regeneration of the pan-
creas and kidney in type 1 diabetic (DMT 1) animals.
To test this hypothesis, we performed experiments in
STZ-induced diabetic mice, at a moment equivalent
to the clinical stage at which human patients are typi-
cally diagnosed with type 1 diabetes [31]. At such
a time, animals were given intravenously either a single
dose of MSC (25  106 cells/kg body weight), or the
vehicle as control. We then evaluated and compared
their pancreatic and renal function and structure.
RESEARCH DESIGN AND METHODS
Research Design
Interventional study in an experimental animal
model, according to protocol summarized in Figure 1.
Animals
C57BL/6 mice (Jackson Laboratory, Bar Harbor,
ME) were housed at constant temperature and humid-
ity, with a 12:12 h light:dark cycle and with standard
diet and water ad libitum. When required, animalswere lightly anesthetized with sevofluorane (Abbott,
Japan). All animal procedures were approved by the
Facultad de Medicina, Clınica Alemana-Universidad
del Desarrollo Ethics Committee.
Type 1 Diabetes Induction
Eight-week-old male mice were lightly anesthe-
tized. STZ (Calbiochem, La Jolla, CA) was dissolved
in 0.1 M citrate, at pH 4.5, and was immediately in-
jected intraperitoneally at a dose of 40 mg/kg, for 5
consecutive days. Normal animals received citrate
buffer only [32].
MSC isolation, Ex Vivo Expansion, and
Characterization
Six- to 8-week-old male C57BL/6 mice were sacri-
ficed by cervical dislocation. Bone marrow cells were
obtained by flushing the femora and tibia with sterile
PBS. After centrifugation, cells were resuspended in
alpha-MEM (Gibco, Auckland, NZ), supplemented
with 10% selected fetal bovine serum (Gibco) and 80
mg/mL gentamicin (Sanderson Laboratory, Chile),
and plated at a density of 1  106 nucleated cells/
cm2. Nonadherent cells were removed after 72 hours
by media change. When foci reach confluence, adher-
ent cells were detached with 0.25% trypsin, 2.65 mM
EDTA, centrifuged, and subcultured at 7000 cells/
cm2. After 2 subcultures, adherent cells were charac-
terized according to their adipogenic and osteogenic
differentiation potential. Immunophenotyping analy-
sis was neither performed for hemopoietic nor mesen-
chymal antigens, as we have previously shown that
nonadherent small round cells positive for CD45,
CD34, or CD14 disappeared after the second or third
passage [7], and surface antigen expression is not uni-
versally well characterized for murine MSCs as it is
for human MSCs [8].
Adipogenic and Osteogenic Differentiation
To induce adipogenic differentiation, confluent
adherent cells were cultured in alpha-MEM, supple-
mented with 1 mM dexamethasone (Sigma-Aldrich,
Steinheim, Alemania), 100 mg/mL 3-isobutyl-1-meth-
ylxanthine (Calbiochem, San Diego, CA), 100 mM
indomethacin (Sigma-Aldrich), and 0.2 UI/mL insu-
lin (Eli Lilly, Indianapolis, IN), replaced every 3
days. After 10 days of stimulation, cell differentiation
into lipid-laden adipocytes was confirmed by Oil
Red O staining (Sigma-Aldrich). To induce osteo-
genic differentiation, confluent adherent cells were
cultured in alpha-MEM medium supplemented with
0.1 mM dexamethasone, 10 mM beta-glycerophos-
phate (Sigma-Aldrich), and 50 mg/mL ascorbate 2-
phosphate (Sigma-Aldrich), replaced every 3 days.
After 21 days of stimulation, cell differentiation into
hydroxyapatite-producing osteoblasts was confirmed
by Alizarin Red staining (Sigma-Aldrich).
MSCs Revert Diabetes and Prevent Its Nephropathy 633Figure 1. Research design. C57BL/6 adult male mice were injected with STZ daily for 5 days. Twenty-five days after the first STZ dose, mice
received 0.5 106 MSCs or the vehicle via the tail vein. Blood glucose level was determined every 2 days. At day 62 post-MSC treatment (day 87
postdiabetes induction), pancreas and kidney function and structure were evaluated.MSC Administration
MSCs (0.5 106), labeled with 8 mg/mLDiI (Invi-
trogen, Eugene, OR) were resuspended in 0.2 mL of
5% mice plasma and administered via the tail vein to
lightly anesthetized mice. Untreated animals received
0.2 mL of 5% mice plasma.
Blood Glucose Determination and Diabetes
Definition
Blood samples were taken from the tail vein of
nonfasted alert animals, and glucose levels were deter-
mined with the glucometer system Accu-Chek Go
(Roche Diagnostic, Mannheim, Germany). Mice
were considered diabetic if glycemia were above 250
mg/dL, on 3 consecutive determinations.
Urinary Glucose Determination
Mice were kept in metabolic cages until they spon-
taneously urinated. Glucose levels were measured with
the glucometer system Accu-Chek Go. Urine was di-
luted in 0.9% NaCl to fit samples to the linear range
of the glucometer system.
Intraperitoneal Glucose Tolerance Test
Six-hour fastingmice were lightly anesthetized and
injected intraperitoneally with 2 mg glucose/g body
weight. Blood glucose levels were determined 15 min-
utes before glucose administration, as well as after 15,
30, 60, 90, 120, and 180minutes of glucose administra-
tion, as described vide supra.
Urinary Albumin Excretion
Excretion of urinary albumin was determined us-
ing albumin:creatinine ratio on morning spot urine
collections. Mice were kept in metabolic cages until
they spontaneously urinated. Urine albumin concen-
tration was determined using the immunoturbidimet-
ric commercial kit from Orion Diagnostica (Espoo,
Finland), whereas urine creatinine concentration was
determined using the picric acid assay from Quımica
Clinica Aplicada (Amposta, Spain).Pancreas and Kidney Histology
Mice were anesthetized by intramuscular injection
of xylazine and ketamine and sacrificed by intracardiac
injection of thiopental. Pancreas and kidneys were rap-
idly removed, fixed with 4% paraformaldehide, and
embedded in paraffin. Pancreatic sections (4 mm)
were stained with hematoxilin-eosin and renal sections
(4-mm) with PAS reagent. Slices were analyzed under
light microscopy, focusing into the pancreas’s islet
and kidney’s glomeruli and interstitial areas. Images
were captured with a digital camera.
Pancreas Double-Label Immunohistofluorescence
Deparaffinized pancreatic sections were incubated
for 2 hours with chicken antihuman insulin from
Chemicon (Temecula, CA) and rabbit antiporcine glu-
cagon from DAKO (Carpinteria, CA). After washing,
the sections were incubated for 1 hour with Alexa
594 conjugated antichicken IgY and Alexa 488 conju-
gated antirabbit IgG from Molecular Probes (Eugene,
OR). Crossreactivity of secondary antibodies was
tested by replacing the target primary antibody with
normal serum. Slices were examined under laser scan-
ning confocal microscopy, and optical sections of 1 mm
were analyzed [33].
Detection of Donor MSCs into the Pancreas and
Kidney
Mice were anesthetized by intraperitoneal injec-
tion of xylazine and ketamine and sacrificed by an in-
tracardiac injection of thiopental. The pancreas and
kidneys were rapidly removed, embedded in OCT (Sa-
kura Finetek, Torrance, CA), and frozen in liquid ni-
trogen. Cryosections (8 mm) were stained with DAPI
0.1 mm g/mL and mounted. Slices were observed un-
der epifluorescence microscopy, with 420-nm and
590-nm filters. Images were captured with a digital
camera and virtually merged.
Statistical Analysis
Data are presented as mean 6 SEM. When com-
paring between experimental groups, a Student’s
t-test was used. For multiple comparisons, ANOVA
634 F. E. Ezquer et al.
MSCs Revert Diabetes and Prevent Its Nephropathy 635Figure 3. Bone marrow-derived MSCs isolated from C57BL/6 adult male mice. Bone marrow cells were cultured in alpha-MEM containing
10% selected fetal bovine serum into plastic dishes. Plastic adherent cells were ex vivo expanded under the same condition (A) and differentiated
into adipogenic (B) or osteogenic (C) lineages. Data are shown as representative cultures from 5 bone marrow samples obtained from 5 different
animals.analyses were performed. P values\0.05 were consid-
ered statistically significant.
RESULTS
To develop DMT 1 mice, we used the well-de-
scribed STZ administration in a 5 low-dose protocol
that induce autoimmune beta-pancreatic islet destruc-
tion [32]. Twenty-five days after the first STZ dose,
mice blood glucose reached its highest level, which
was 2.7 times larger than in normal individuals (404
mg/dL 6 17 SEM versus 151 mg/dL 6 9 SEM;
Figure 2A). Together, in DMT 1 mice glycosuria
was 116 times higher than in normal animals (10,000
mg/dL 6 800 SEM versus 86 mg/dL 6 7 SEM;
Figure 2B) and concomitantly, a morphologic assess-
ment of pancreatic sections stained with hematoxylin
and eosin showed a massive destruction of beta-pan-
creatic islets (Figure 2C). As expected, less insulin-
and more glucagon-positive cells were observed in
remnant islets compared to normal beta-pancreatic
ones (Figure 2D). On the other hand, on day 25
post-STZ administration, DMT 1 mice presented
mild albuminuria (13 mg/mg 6 1 SEM versus 4.1 mg/
mg 6 0.4 SEM; Figure 2E), but few or no renal histo-
pathologic changes (Figure 2F). Without insulin sup-
plementation, all DMT 1 animals survived up to 3
months, maintaining their body weight constant and
increasing food and water intake slightly (data not
shown). Thus, 25 days post-5 low-dose STZ adminis-
tration, C57BL/6 mice were in a diabetic stage similar
to that of human patients, who were already diagnosed
with type 1 diabetes [31].DMT 1 mice at 25 days post-STZ were randomly
assigned into 2 groups: 1 received 0.5 106 bone mar-
row-derivedMSC that have been ex vivo expanded and
characterized according to their plastic adherence
(Figure 3A), adipogenic (Figrue 3B), and osteogenic
(Figure 3C) differentiation potential, and the other
group received the vehicle. Within a week after MSC
administration, blood glucose levels were significantly
reduced (day 32) and decreased until reaching almost
euglycemic values a month later (day 62, 209 mg/dL
6 23 SEM; Figure 4A). Hyperglycemia correction
lasted at least for 2 months and correlates with glycos-
uria reversion (day 87, 139 mg/dL 6 26 SEM;
Figure 4B). In contrast, untreated DMT 1 mice re-
mained with high levels of glycemia and glycosuria un-
til the end of the study period (day 87, 390mg/dL6 32
SEM, and 6867 mg/dL 6 485 SEM, respectively;
Figure 4A and B).
We next evaluated whether the recovery of glyce-
mia toward normal levels correlates with pancreatic
histologic changes. Whereas untreated DMT 1 mice
exhibited morphologic abnormal islets, MSC-treated
DMT 1 animals presented typical beta-pancreatic is-
lets that were smaller than those of nondiabetic mice
(Figure 4C). Interestingly, only in DMT 1 mice that
receivedMSCs beta-pancreatic islets were architectur-
ally organized as in normal mice, with insulin-produc-
ing cells located centrally and glucagon-producing
cells located peripherally (Figure 4D). However, pan-
creatic islets were less abundant inMSC-treated DMT
1 mice than in normal animals (day 87, 11 6 1 SEM
versus 27 6 2 SEM; Figure 4E). Furthermore, MSC-
treated DMT 1 mice exhibited abnormal glucoseFigure 2.Characterization of diabetes stage in type 1 diabetic mice that will be treated withMSCs. C57BL/6 adult malemice were injected either
with 0.1 M citrate buffer (normal) or 40 mg/kg STZ in 0.1 M citrate buffer, daily for 5 days (DMT1). Twenty-five days after the first STZ dose,
blood glucose level was determined in venous blood samples obtained from alert nonfasted animals (A); glycosuria was determined in morning
spot urine samples (B); pancreas histology was studied in serial 4 mm hematoxilin/eosin-stained sections, observed under light microscopy and
focusing on islets structures indicated by arrows (C); beta-pancreatic islets were characterized by immunohistofluorescence, according to insulin-
and glucagon-producing cells presence and distribution (D); urinary albumin excretion was determined in morning spot urine samples according
to albumin to creatinine concentration assessed by commercial kits (E); and renal histology was studied in serial 4 mm PAS-stained sections, ob-
served under light microscopy and focusing on glomeruli structures (F). Quantitative data are shown as mean6 SEM for 16 animals per exper-
imental group. Qualitative data are shown as a representative section from 25 sections per animal, for 4 animals per experimental group.
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betic animals (Figure 4F).
Two months after MSC administration, albumin-
uria was reduced only in MSC-treated DMT 1 mice
(3.5 mg/mg 6 0.9 SEM at day 87; Figure 5A). Histo-
logic kidney analyses showed normal glomeruli in
such animals. In contrast, glomerular hyalinosis and
mesangial expansion were observed in untreated
DMT 1 mice (Figure 5B).
Thus, MSC administration contributes to beta-
pancreatic islet regeneration and avoids renal damage
in DMT 1 mice. To test if the therapeutic effect ob-
served was related to cell lodgement into the pancreas
and kidney, we administered DiI-labeled MSCs into
DMT1mice and looked for the presence of donor cells
in those organs. As seen in Figure 6A and B, 62 days af-
ter administrationwewere able to find rareDiI-labeled
cells in all samples of the pancreas and kidney analyzed.
Hence, at a very low rate, MSC administered endove-
nously effectively reached and persisted into the pan-
creas and kidney of DMT 1 animals.
DISCUSSION
In human diabetic patients, hyperglycemia initi-
ates after a significant lost of functional insulin-pro-
ducing cells, which seems to be irreversible [31,34].
Currently available diabetes treatments do not focus
on beta-pancreatic cell regeneration. Hyperglycemia
is treated either by oral glucose-lowering agents or in-
sulin administration. These treatments intend to pro-
vide an accurate control of blood glucose level, but
they do not prevent severe long-term complications
of diabetes, like diabetic nephropathy, associated
with premature morbimortality [35,36]. Thus, an ideal
diabetes treatment should recover, at least, pancreas
and kidney functions in patients with already estab-
lished disease.
We show here that bone marrow-derived MSCs
given endovenously contribute to the regeneration
of pancreas and kidney in an animal model of type 1
diabetes.
We chose the mice model of 5 low-dose STZ-in-
duced type 1 diabetes because it is well documented
to produce insulinitis and hyperglycemia, because of
beta-pancreatic cells autoimmune destruction, mim-
icking the etiology of human type 1 diabetes [37].We observed that 25 days after the first STZ dose,
DMT 1 mice were hyperglycemic and severely glyco-
suric, signs indicative of massive destruction of beta-
pancreatic islets. Together, animals did not recover
spontaneously, and 2 months after diabetes onset, mi-
croalbuminuria, glomerular hyalinosis, and mesangial
expansion were observed. Thus, the animal model
used here shares the causes, signs, main complication,
and evolution of human type 1 diabetes [31].
In these DMT1mice, a single dose of undifferenti-
ated bone marrow-derived MSCs administered when
diabetes signs were evident, proved to revert hypergly-
cemia and glycosuria almost to normal levels. These
corrections associatedwith beta-pancreatic islets regen-
eration because in MSC-treated DMT 1 mice we ob-
served an increase in the number of beta-pancreatic
islets compared to untreated DMT 1 mice. Addition-
ally, the morphologic analysis of these islets showed
that they were architecturally normal, proving that
MSC administration not only increased the number of
insulin-producing cells, but also restricted glucagon-
producing cell expansion, known as a compensatory re-
sponse that complicates hyperglycemia management in
diabetic individuals [38]. Thus, hyperglycemia correc-
tion inMSC-treated DMT 1mice was because of insu-
lin production by newly regenerated beta-pancreatic
islets. Nevertheless, the new beta-pancreatic islets
were less abundant and smaller than in normal individ-
uals probably because of an incomplete regeneration.
This might explain why a single dose of MSCs did not
correct the abnormal glucose tolerance curves observed
in DMT1 mice. Hence, the systemic administration of
MSCs into DMT 1 mice reverted the hyperglycemia
condition only under normal diet glucose ingestion.
To manage massive glucose intake, it would be neces-
sary to increase thenumber of regeneratedbeta-pancre-
atic islets.Wehypothesized that a second dose ofMSCs
might be a good strategy to attain that.
Microalbuminuria reversion, together with the fact
that MSC-treated diabetic mice did not develop renal
histopathologic alterations, as found in untreated dia-
betic animals, prove that MSC administration recov-
ered and hindered further impairment in renal
function as it precluded glomeruli structural damage
in diabetic individuals.
Despite the use of DiI, a label that faded during cell
proliferation, we found some donor MSCs in theFigure 4. Reversion of the hyperglycemic condition and regeneration of beta-pancreatic islets in MSC-treated type 1 diabetic mice. Twenty-five
days after the first STZ dose, mice received 0.2 mL of 5% mice plasma (DMT 1) or 0.5  106 MSCs resuspended in 0.2 mL of 5% mice plasma
(DMT11MSC), via the tail vein. Blood glucose level was determined every 2 days in alert nonfasted animals using the Accu-ChekGo system (A)
62 days post-MSC administration, glycosuria was determined in morning spot urine samples (B); pancreas histology was studied in serial 4 mm
hematoxilin/eosin-stained sections, observed under light microscopy and focusing on islets structures indicated by arrows (C); beta-pancreatic
islets were characterized by immunohistofluorescence according to insulin (red)- and glucagon (green)-producing cells presence and distribution
(D), and were quantified (E). Individual glucose tolerance was assessed by intraperitoneal glucose tolerance test, administering 2 mg glucose/g
body weight and determining blood glucose levels (F). Quantitative data are shown as mean6 SEM for 8 animals per experimental group. Qual-
itative data are shown as representative sections from 25 sections per animal, for 4 animals per experimental group.
638 F. E. Ezquer et al.Figure 5. Prevention of renal damage in MSC-treated type 1 diabetic mice. Twenty-five days after the first STZ dose, mice received 0.2 mL of
5% mice plasma (DMT1) or 0.5  106 MSC resuspended in 0.2 mL of 5% mice plasma (DMT11MSC) via the tail vein. Sixty-two days post-
MSC administration, urinary albumin excretion was determined inmorning spot urine samples according to albumin to creatinine concentration
assessed by commercial kits (A). Renal histology was studied in serial 4 mm PAS-stained sections, observed under light microscopy and focusing
on glomeruli structures (B). Quantitative data are shown as mean 6 SEM for 8 animals per experimental group. Qualitative data are shown as
representative sections from 25 sections per animal for 8 animals per experimental group.DMT 1 mice pancreas and kidney even 2 months after
administration. These data were not unexpected, as
Lee et al. [29] detected a small number of infused cells
in pancreatic islets and/or glomeruli of immunodefi-
cient NOD/SCID diabetic mice, after 15 days of infus-
ing a 10-fold larger number of MSCs than the one we
administered [29]. Thus, either in type 1 or in incom-
plete type 2 diabetes models, the beneficial effect of
MSC administration occurs besides their low rate of
lodgement [39]. As we have only searched for the pres-
ence of administered MSCs in the pancreas and kid-
ney, we do not know if MSCs reached other organs
also damaged by the hyperglicemic condition, like
the retina, nerves, and vessels [40].For technical reasons, we were unable to search for
cellular mechanisms associated with MSC therapeutic
effects observed in DMT 1 mice. Nevertheless, the
long-lasting persistence of injected cells suggests a
direct effect of MSCs in pancreas and kidney regener-
ation. Either MSCs might differentiate into insulin-
producing cells or they might induce endogenous
progenitor proliferation/differentiation. The fact that
newly generated beta-cells are not destroyed by the
immune system might be explained either because
they differentiate fromMSCs known to be hypoimmu-
nogenic [41], or because of the presence of an immu-
nosuppressive microenvironment in the pancreas
sustained by undifferentiated MSCs [42,43]. WithFigure 6.MSChoming into the pancreas and kidney of type 1 diabeticmice. Twenty-five days after the first STZ dose injectionmice received 0.2
mL of 5% mice plasma (DMT1) or 0.5  106 DiI labeled-MSCs resuspended in 0.2 mL of 5% mice plasma (DMT1 1MSC) via the tail vein.
Sixty-two days post-MSC administration, pancreas (A) and kidney (B) cryosections (8 mm) were obtained, stained withDAPI, and observed under
epifluorescence microscopy. Data are shown as a representative section from 15 sections per animal for 4 animals per experimental group.
MSCs Revert Diabetes and Prevent Its Nephropathy 639regard to the kidney, MSCs might replace damaged
renal cells in DMT 1 mice as has been described in
acute renal injury models [27,28]. Alternatively,
MSCs might scavenge cytotoxic molecules, modulate
the inflammatory process, or promote neovasculariza-
tion avoiding kidney damage [43]. As MSC adminis-
tration also reverts glycosuria, one of the main noxa
to renal cells, we suggest that regeneration surpasses
progressive damage in the kidney of MSC-treated
mice, thus preventing diabetic nephropathy.
The effectiveness of the administration of a single
dose of MSCs in the experimental model of type 1 di-
abetic mice is of particular interest, as it corrects dia-
betic manifestations (hyperglycemia and glycosuria)
and also reverts microalbuminuria and precludes renal
structural damage. By contrast, in the incomplete type
2 diabetes model used by Lee et al. [29], MSC admin-
istration in a concentration 10-fold larger than the one
we used does not correct hyperglycemia, but only pre-
vents further increases. Thus, systemic administration
of MSCs appears to be therapeutic in type 1 diabetic
animals, but only preventive in type 2 diabetic ones.
Results presented here should encourage clinical
studies to evaluate the potential benefit of MSC ad-
ministration, because their infusion in humans is feasi-
ble and safe [21].
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